Effect of GNAQ alteration on RANKL-induced osteoclastogenesis in human non-small-cell lung cancer. Issue 1 (January 2020)

• Record Type: Journal Article
• Authors: Choi, Ji-Yoon; Lee, Yun Sun; Shim, Da Mi; Seo, Sung Wook
• Is Part Of: Bone & joint research. Volume 9:Issue 1(2020)
• Page Start: 29
• Page End: 35
• Publication Date: 2020-01
• Subjects: GNAQ -- RANKL -- Osteoclastogenesis -- Bone -- Lung cancer; Musculoskeletal system -- Periodicals; 573.705
• DOI: 10.1302/2046-3758.91.BJR-2019-0085.R2
• Languages: English
• ISSNs: 2046-3758

Abstract

Abstract : Aims: Receptor activator of nuclear factor-κB ligand (RANKL) is a key molecule that is expressed in bone stromal cells and is associated with metastasis and poor prognosis in many cancers. However, cancer cells that directly express RANKL have yet to be unveiled. The current study sought to evaluate how a single subunit of G protein, guanine nucleotide-binding protein G(q) subunit alpha (GNAQ), transforms cancer cells into RANKL-expressing cancer cells. Methods: We investigated the specific role of GNAQ using GNAQ wild-type cell lines (non-small-cell lung cancer cell lines; A549 cell lines), GNAQ knockdown cell lines, and patient-derived cancer cells. We evaluated GNAQ, RANKL, macrophage colony-stimulating factor (M-CSF), nuclear transcription factor-κB (NF-κB), inhibitor of NF-κB (IκB), and protein kinase B (Akt) signalling in the GNAQ wild-type and the GNAQ -knockdown cells. Osteoclastogenesis was also evaluated in both cell lines. Results: In the GNAQ -knockdown cells, RANKL expression was significantly upregulated (p < 0.001). The expression levels of M-CSF were also significantly increased in the GNAQ -knockdown cells compared with control cells (p < 0.001). GNAQ knockdown cells were highly sensitive to tumour necrosis factor alpha (TNF-α) and showed significant activation of the NF-κB pathway. The expression levels of RANKL were markedly increased in GNAQ mutant compared with GNAQ wild-type in patient-derived tumour tissues. Conclusion: The present study reveals that the alterations of GNAQ activate NF-κB pathway in cancers, which increase RANKL and M-CSF expression and induce osteoclastogenesis in cancers. Cite this article: Bone Joint Res. 2020;9(1):29–35.